Medcura, Inc. is a commercial stage medical device company which is currently focused on improving the effectiveness of hemostatic products for areas such as surgical, medical and consumer applications.
It recently received $7.4 million in new capital, which included the sale of Series A Preferred stock and common stock from a number of investors from the Maryland Investment Incentive Program.
The new investment funds will be used to support the development of leading surgical products and candidates for clinical evaluation.
Medcura CEO Larry Tiffany said that Medcura’s growth has reached a pivotal point and that the company is providing products that have a positive impact on the lives of patients and society at large.
With the fresh funds, the development of Medcura’s products can be accelerated, and their commercial scope expanded to send life-saving technology around the world.
At present, Medcura’s biggest mission is to continue to develop and commercialize the hemostasis and wound treatment product lines.
These products are leading the way in terms of expansion in internal use and surgical procedures.
Medcura’s three main products include:
Rapid-Seal: is a market leader in antibacterial and high performance first aid.
LifeFoam: a breakthrough device for injured organs and military trauma.
LifeGel: product used in surgery.
The FFI Foundation believes that Medcura is a right choice for its ideal investment and is ready to support the company’s growth in the next phase. Medcura was able to effectively utilize the funding from the US Army as well.
With numerous FDA certifications, patents and recognition through numerous publications, Medcura is building a solid company. With the recent Series A funding, Medcura is completing an important milestone.
Medcura will continue with planned preclinical development and an Investigational Device Waiver (IDE) submission to the US FDA, which will allow clinical trials to begin for its LifeGel product.
The military is where Medcura’s products have a chance to be used and treated for serious injuries or trauma. The company’s LifeFoam has been shown to provide rapid and effective hemostasis for severe trauma.
Moreover, studies have shown that LifeFoam uses core ingredients that are benign and are absorbed by the body.
